Protocol Ledger

NCT04927481 · Phase II · TERMINATED

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Interventional Phase II clinical trial protocol NCT04927481 sponsored by CSPC ZhongQi Pharmaceutical Technology Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-11 Enrollment: 28 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04927481
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)28 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04927481
Protocol FieldVerified Registry Value
NCT IdentifierNCT04927481
Consolidated Lead SponsorCSPC ZhongQi Pharmaceutical Technology Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment28 participants (ACTUAL)
Registered Start Date2021-06-11
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI